Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER.
Farlow M, et al. Among authors: friedrich s.
Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.
Alzheimers Dement. 2012.
PMID: 22672770
Clinical Trial.